drugset / Trial / NCT00652483

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

NCT00652483

Phase 3 Completed 433 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension

Timeline

Start
2003-05
Primary completion
2003-12
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.1 % Other
Subject Brimonidine Small molecule 0.2 % Other